Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

Summary

To compare the incidence of acute kidney injury (AKI) post percutaneous coronary intervention (PCI) in a Dapagliflozin treated group versus a group managed with the usual standard of care.

Timeline

Start

2024-09-01

Primary completion

2025-06

Completion

2025-06

Outcome

Outcome not reported

Stopped: “Laboratory UNGAL”

Drugs

Indications